Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
Why the study?
The authors examined the effects of dapagliflozin according to age due to potential concerns regarding the efficacy and safety of therapies in elderly patients with HFrEF.
Does dapagliflozin reduce worsening heart failure or cardiovascular death in patients with HFrEF across different age groups?
Population
4744 patients aged 22 to 94 years with HFrEF (NYHA class ≥II, LVEF ≤40%)
Comparison
Dapagliflozin vs placebo according to age
Design
Randomized controlled trial subgroup analysis
Authors
Discussion
Loading...
Member takes
Implication
Supports dapagliflozin use across HFrEF ages including elderly; confirms consistent benefit without interaction.
Structured PICO
Does dapagliflozin reduce worsening heart failure or cardiovascular death in patients with HFrEF across different age groups?
P
Population
4,744 patients aged 22 to 94 years (mean age 66.3) with heart failure and reduced ejection fraction (NYHA class II or greater, LVEF ≤40%, modest elevation of NT-proBNP). Key exclusions: systolic blood pressure <95 mm Hg and estimated glomerular filtration rate <30 mL/min/1.73 m2.
I
Intervention
Dapagliflozin added to other guideline-recommended therapies
C
Comparator
Placebo added to other guideline-recommended therapies
O
Outcome
Composite of an episode of worsening heart failure (heart failure hospitalization or urgent heart failure visit) or cardiovascular death, whichever occurred firstcomposite
Dapagliflozin provides consistent cardiovascular benefits and is well-tolerated in patients with HFrEF regardless of age, including the elderly.
Cite This Study
Martínez et al. (2019) studied this question.